Cover Image
Market Research Report

United States Market for Rheumatoid Arthritis Pharmacotherapeutics

Published by Frost & Sullivan Product code 246427
Published Content info 110 Pages
Delivery time: 1-2 business days
Back to Top
United States Market for Rheumatoid Arthritis Pharmacotherapeutics
Published: July 5, 2012 Content info: 110 Pages


This research service covers the United States rheumatoid arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed used on top of background standard of care. Included in the study are products of the market and products in development, as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. Treatment paradigms for rheumatoid arthritis and patient flow dynamics through lines of therapy are also included. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors, non-TNF biologics, and novel oral disease-modifying antirheumatic drugs (DMARDs).

Table of Contents
Product Code: NB33-01-00-00-00

Table of Contents

1. Rheumatoid Arthritis Pharmacotherapeutics Market

  • Research Service
    • Executive Summary
    • Market Overview
  • Total Rheumatoid Arthritis Pharmacotherapeutics Market
    • External Challenges: Drivers and Restraints
    • Forecasts and Trends
    • Demand Analysis
    • Market Share and Competitive Analysis
  • United States Market for Rheumatoid Arthritis Pharmacotherapeutics - Analysis by Market Segment
    • TNF Inhibitor Segment Breakdown
    • Non-TNF Biologics Segment Breakdown
    • Novel Oral DMARDs Segment Breakdown
  • The Last Word
    • Three Big Predictions
  • Appendix
    • Appendix
Back to Top